Medindia

X

Bradmer appoints Paul Van Damme Chief Financial Officer

Thursday, September 13, 2007 General News J E 4
Advertisement
TORONTO, Sept. 12 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., abiopharmaceutical company dedicated to the development and commercializationof cancer therapies, today announced that the Board of Directors has appointedPaul J. Van Damme, MBA, CA, to the position of Chief Financial Officereffective September 12, 2007. Mr. Brian Brohman will continue to serve in aleadership position as Chief Business Officer of the Company.

"Mr. Van Damme brings significant expertise in corporate finance,corporate governance and compliance, and investor relations to the managementteam at Bradmer," said Dr. Alan M. Ezrin, Chief Executive Officer of Bradmer."With an extensive background in the life science sector for public companieslisted in both Canada and the United States, Paul adds tremendous depth to ourteam and will play a key role in our future growth."

Mr. Van Damme has previously held the senior finance position on themanagement team of three publicly traded life science companies, Vasogen Inc.,Lorus Therapeutics Inc. and NPS Pharmaceuticals, Inc. (formerly AllelixBiopharmaceuticals Inc.). Mr. Van Damme currently serves on the Board ofDirectors and the Audit Committee of the Ontario Genomics Institute. Earlierin his career, Mr. Van Damme was an Audit Manager for PricewaterhouseCoopers.He is a member of a number of professional associations including theAssociation for Investment Management and Research and Financial ExecutivesInternational. He received his Master in Business Administration from theRotman School of Management at the University of Toronto.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of new and innovative cancer therapies.Bradmer's lead clinical candidate, Neuradiab, was developed at Duke UniversityMedical Center as a proprietary therapy for a particularly aggressive form ofbrain cancer, glioblastoma multiforme. To date, over US$60 million in grantsand related support has driven research and development of the licensedtreatment, which has been delivered to over 200 patients with promisingresults and has completed Phase II clinical trials at Duke University. Bradmeris currently in the process of organizing a prospective multi-center clinicaltrial of the licensed treatment. Neuradiab has been granted Orphan Drug Statusby both the U.S. Food and Drug Administration and the European MedicinesAgency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registeredunder the Securities Act of 1933, as amended (the "Securities Act") or anystate regulatory agency in the United States. The resale or transfer by a U.S.investor of such common shares of Bradmer Pharmaceuticals Inc. is subject tothe requirements of Rule 904 of Regulation S of the Securities Act or suchother applicable exemption thereunder, and other applicable state securitieslaws.

Except for historical information, this press release may containforward-looking statements, which reflect the Company's current expectationregarding future events. These forward-looking statements involve risk anduncertainties, which may cause but are not limited to, changing marketconditions, the successful and timely completion of clinical studies, theestablishment of corporate alliances, the impact of competitive products andpricing, new product development, uncertainties related to the regulatoryapproval process and other risks detailed from time to time in the Company'songoing quarterly and annual reporting.

SOURCE Bradmer Pharmaceuticals Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
AdCare Health Systems, Inc. Reports Discontinuatio...
S
Thermo Fisher Scientific to Present at Upcoming In...